

SUSTAINED NANO SYSTEMS, LLC

**25 Health Sciences Drive
Stony Brook, NY 11790**

**6100 Hollywood Boulevard,
Suite 207,
Hollywood, Florida 33024**

Subject: FROM THE CHAIRMAN

Date: January 18, 2023

From: blibin@sustainednanosystems.net

AN SNS UPDATE

2022 was a busy and productive year at Sustained Nano Systems. We entered the year with the new SNS Densomere technology having already shown effectiveness in its ability to release drugs over the long term (our studies went out one year) and continue to maintain its biologic activity. This was further proven by testing molecules placed into SNS Densomeres by our pharmaceutical clients.

However, to further confirm our ability to control drug release, we needed to manage not only drug duration but the ability to control the amount of initial release, or "burst", a common effect that limits many delivery systems.

I am pleased to say that through our research we are now able to minimize or eliminate that initial "burst" through a new process that may be patentable.

Therefore, we now believe we can offer to drug development companies, including those in the field of biosimilars and biologics, a means to incorporate their drugs into our Densomere Technology in two formats:

1. A Therapeutic Densomere, which allows a significant amount of drug to be initially released over the first four to six weeks to treat an ongoing disease, and then converts into a maintenance dose for as long as required. Other drugs now being sold require several injections of different doses to achieve this result. SNS has it all built into its Densomere.
2. A Continuous Dose Release Densomere that minimizes or eliminates the initial burst. For example, a drug that may have a toxic response, or a drug like insulin, where an excessive amount is contraindicated.

Secondly, as you may be aware, SNS had developed a method that provides for terminal sterilization of proteins and other large molecules using E-Beam radiation without affecting molecular integrity or activity. To our knowledge, SNS is the first to provide such sterilization during manufacturing without the need for cumbersome and costly aseptic protocols. Basically, that means you can boil an egg without destroying the protein.

As a result of reaching these objectives, SNS will now play an ever expanding role in licensing its Densomere technology to the Pharmaceutical Industry.

I am also including below the response by the ARVO Journal reviewing our newest article on sustained release, which includes a comment that it is the first time the editor has ever read a paper without the need for a single change. That is quite a compliment.

We look forward to 2023 being an exciting year.

Sincerely,

Barry Libin, DDS, MSD, MS
Chairman of the Board
CEO, Sustained Nano Systems, LLC

COMMENTS FROM THE ARVO EDITORS:

"The reviewers and EBM find your MSS suitable for publication pending adequate addressing of raised minor concerns stated below. Thank you for choosing TVST journal.

The manuscript is well written and the results support the conclusions being drawn. Ocular delivery of therapeutic products, especially antibodies remains a critical field and this manuscript does add valuable information.

This manuscript reports research on sustained ocular delivery of an anti-VEGF whole Ab (bevacizumab) using PLGA-based extended release.

. . . . This is an outstanding paper that presents work on a sustained release method for administration of various macromolecules, with antibody therapies such as bevacizumab being the specific molecule tested in this paper. The authors present in vitro and in vivo data demonstrating sustained release and long term antineovascular in vivo efficacy. Overcoming barriers to sustained ocular release of macromolecules like anti-VEGF antibodies has been the holy grail of antineovascular therapy.

. . . I have never before recommended that a manuscript be "accepted as is", but I will do so in this case. The authors should be congratulated on their work."